Skip to Main Content

An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)

Conditions

Diseases of the Cardiovascular System

Phase III

What is the purpose of this trial?

Brief Summary:

This is a Phase 3, prospective, open-label, international, multicentre study of Flurpiridaz (18F) Injection for PET MPI in patients referred for ICA because of suspected CAD.

  • Trial with
    GE Healthcare
  • Start Date
    01/29/2019
  • End Date
    08/30/2020
Trial Image

For more information about this study, contact:

Donna McMahon

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    03/01/2019
  • Study HIC
    #2000023850